A Study of LY3015014 in Participants With High Cholesterol

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01890967
First received: June 27, 2013
Last updated: June 27, 2014
Last verified: June 2014
  Purpose

This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol. The study will also investigate how the body processes the drug and how the drug affects the body. Participants will remain on a stable diet and will continue taking cholesterol-lowering medications (statins with or without ezetimibe). After signing the informed consent document, the participant will complete a screening/run-in period that will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks. After the treatment period, the participants will complete a follow-up period lasting approximately 8 weeks for a total study duration ranging from approximately 25 to 32 weeks.


Condition Intervention Phase
Hypercholesterolemia
Drug: LY3015014
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Percentage Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage Change from Baseline in Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Non-HDL-C, Apolipoprotein B (Apo B), Apolipoprotein A-1 (Apo A-1), Lipoprotein(a) (Lp[a]) [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
  • Change from Baseline in high sensitivity C-Reactive Protein (hsCRP) [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
  • Percentage of Participants Who Develop Treatment Emergent Anti-LY3015014 Antibodies [ Time Frame: Baseline through Week 24 ] [ Designated as safety issue: No ]
  • Percentage Change from Baseline in Total and Free Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) at Steady-State for LY3015014 [ Time Frame: Pre-dose through Week 16 ] [ Designated as safety issue: No ]
  • Percentage of Participants with an Injection Site Reaction [ Time Frame: Baseline through Week 24 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 528
Study Start Date: June 2013
Study Completion Date: June 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 20 mg LY3015014 Q4W

20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.

Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe.

Drug: LY3015014
Administered SC
Experimental: 120 mg LY3015014 Q4W

120 mg LY3015014 given SC Q4W for 16 weeks.

Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe.

Drug: LY3015014
Administered SC
Experimental: 300 mg LY3015014 Q4W

300 mg LY3015014 given SC Q4W for 16 weeks.

Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe.

Drug: LY3015014
Administered SC
Experimental: 100 mg LY3015014 Q8W

100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.

Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe.

Drug: LY3015014
Administered SC
Experimental: 300 mg LY3015014 Q8W

300 mg LY3015014 given SC Q8W for 16 weeks.

Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe.

Drug: LY3015014
Administered SC
Placebo Comparator: Placebo Q4W

Placebo given SC Q4W for 16 weeks.

Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe.

Drug: Placebo
Administered SC

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with high low density lipoprotein (LDL) cholesterol
  • Are on stable daily dose of a statin or have a history of statin intolerance
  • Men with a partner who can become pregnant must agree to use barrier protection during sexual intercourse to prevent pregnancies
  • Women who cannot become pregnant, or women who are not pregnant or breast feeding and agree to use a reliable method of birth control to prevent pregnancies

Exclusion Criteria:

  • Have high cholesterol due to another disease or have a rare and serious form of hereditary high cholesterol
  • Have had recent heart attack, stroke, blood clot or heart surgery, have planned heart or blood vessel surgery, or has a heart that does not pump sufficiently well
  • Have poorly controlled high blood pressure
  • Have diabetes that requires an injectable medication (including insulin), or have diabetes that is poorly controlled
  • Have thyroid blood test that is outside normal range
  • Have a history of adrenal gland disorder
  • Have a history of vitamin E deficiency or fat malabsorption syndrome
  • Have poor kidney function
  • Have active liver or gall bladder disease, history of hepatitis or liver blood tests that are high
  • Have a history of muscle disease including muscle damage from a medicine or muscle blood test that is high
  • Are anemic (low red blood cell counts)
  • Have a history of allergy or intolerance to other antibody medications
  • Have a history of human immunodeficiency virus infection (HIV) infection
  • Are likely to have a major operation or be hospitalized during the study
  • Have chronic alcohol or drug abuse or dependency
  • Have or suspected to have any cancer or malignant tumor
  • Have an active serious infection
  • Have started or stopped taking a statin or ezetimibe medication, or changed statin dose regimen recently
  • Are on a statin regimen other than daily dosing (for example, an every-other-day statin regimen)
  • Have recently used simvastatin (highest dose level), fibrates, bile acid binders, niacin, probucol, or over-the-counter/health food preparations to lower cholesterol (such as red yeast rice, fish oil, omega 3 fatty acid)
  • Have undergone LDL apheresis in the past 1 year
  • Have recently used steroids, cyclosporine or isotretinoin
  • Have recently used an immunosuppressive therapy
  • Have recently received treatment with another antibody medication
  • Are currently using medications injected into the skin , except for single injections (for example flu vaccines) or injections into muscles
  • Are currently on a prescription or over-the-counter medicine for weight loss or are on a very low carbohydrate diet
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01890967

  Show 49 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01890967     History of Changes
Other Study ID Numbers: 14853, I5S-MC-EFJE
Study First Received: June 27, 2013
Last Updated: June 27, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Japan: Pharmaceuticals and Medical Devices Agency
Czech Republic: Ethics Committee
Czech Republic: State Institute for Drug Control
Denmark: Ethics Committee
Denmark: Danish Health and Medicines Authority
Netherlands: Medical Ethics Review Committee (METC)
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Poland: Ethics Committee
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products

Keywords provided by Eli Lilly and Company:
low density lipoprotein, heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on July 22, 2014